Press Releases ProQR Therapeutics N.V.

Equities

PRQR

NL0010872495

Market Closed - Nasdaq Other stock markets 01:30:00 28/06/2024 am IST			5-day change	1st Jan Change
1.65 ^USD	0.00%		-3.51%	-16.67%

22/05	ProQR Therapeutics N.V. Approves the Appointment of Gerard Platenburg as Management Board Member and Martin Maier as Supervisory Board Member	CI
09/05	Transcript : ProQR Therapeutics N.V. - Special Call

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

ProQR Announces Presentation on its Axiomer RNA Editing Technology at RNA Editing Summit	19/06	AQ
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit	18/06	GL
ProQR Therapeutics N : Annual General Meeting Results - Form 6-K	23/05	PU
ProQR Announces First Quarter 2024 Operating and Financial Results	09/05	GL
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases	08/05	GL
ProQR Highlights Upcoming Presentations on Axiomer RNA Editing at ASGCT 27th Annual Meeting	23/04	AQ
ProQR Therapeutics N : AGM 2024 Notice and Agenda	23/04	PU
ProQR Therapeutics N : AGM 2024 AoA one-tier Board English redline	23/04	PU
ProQR Therapeutics N : AGM 2024 AoA one-tier Board English clean	23/04	PU
ProQR Therapeutics N : AGM 2024 Board Compensation Policy one-tier Board	23/04	PU
ProQR Therapeutics N : AGM 2024 Equity Incentive Plan one-tier Board redline	23/04	PU
ProQR Therapeutics N : AGM 2024 Equity Incentive Plan one-tier Board clean	23/04	PU
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024	23/04	GL
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting	23/04	GL
ProQR Therapeutics N : AGM 2024 Explanatory Notes	23/04	PU
ProQR Therapeutics N : AGM 2024 POA Registered Shareholders	23/04	PU
ProQR Achieves Successful Defense of New Challenge to its Axiomer IP Portfolio	22/04	AQ
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio	19/04	GL
ProQR Announces Year End 2023 Operating and Financial Results	13/03	GL
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing	15/02	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ProQR Therapeutics N.V.

Equities

PRQR

NL0010872495

Press Releases

Filters